DAS-001 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
11Myasthenia gravis1

11. Myasthenia gravis


Clinical trials : 332 Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04226170
(ClinicalTrials.gov)
April 8, 20219/1/2020Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia GravisA Phase II, Study to Evaluate the Safety and Tolerability of Pyridostigmine When Given With Ondansetron to Subjects With Anti-AchR Positive Myasthenia GravisMyasthenia GravisDrug: DAS-001DAS-MG, IncNULLRecruiting18 YearsN/AAll24Phase 2United States